Andrew James King - Feb 10, 2023 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role
Chief Scientific Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Stock symbol
KDNY
Transactions as of
Feb 10, 2023
Transactions value $
-$56,806
Form type
4
Date filed
2/15/2023, 03:39 PM
Previous filing
Feb 2, 2023
Next filing
Apr 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDNY Common Stock Options Exercise +6.8K +45.11% 21.9K Feb 10, 2023 Direct F1
transaction KDNY Common Stock Sale -$56.8K -2.39K -10.93% $23.75 19.5K Feb 10, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Restricted Stock Units Options Exercise $0 -6.8K -50% $0.00 6.8K Feb 10, 2023 Common Stock 6.8K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3 Each RSU represents a contingent right to receive one share of Issuer's common stock.
F4 The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.